Company intelligence / Profile preview

EMBL Ventures

Heidelberg, Baden-Württemberg, Germany

Ownership: Private
Employees: ~5
Development stage: Other

Overview

EMBL Ventures is a Heidelberg-based venture capital firm investing in early-stage European life sciences, particularly in novel therapeutics, platforms, and diagnostics. It does not directly develop clinical-stage assets; instead, it invests in biotech companies, some of which reach clinical development. Its portfolio includes companies focused on new modalities like oncolytic virus therapy and biologics, with successful exits such as the acquisition of ViraTherapeutics.

Modalities: Small moleculeMonoclonal antibodyOncolytic virus therapyGene therapyDeviceBiologicAntibody
Industry: Investors

Partnerships

Boehringer Ingelheim (via portfolio: ViraTherapeutics)Bruker (via portfolio: Luxendo)

Beyond the preview

Go deeper on EMBL Ventures.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EMBL Ventures.

Explore the full profile